THE CHILDRENS HOSPITAL LOS ANGELES
The intestinal epithelium is continuously exposed to high concentrations of bacteria. Intestinal epithelial cells (enterocytes) express pathogen pattern recognition Toll-like receptors (TLR), and produce inflammatory factors in response to stimulation with luminal bacteria or their TLR ligands. These responses are critical for gut maintenance because they promote mutualistic relationship between epithelium and commensal flora. Although intestinal epithelium can sense bacteria, it normally avoids dramatic inflammation by developing tolerance, a long lasting inhibition of inflammatory responses. Failure to develop or maintain tolerance to commensal bacteria can be regarded as an underlying cause of the intestinal inflammatory disorders. Unfortunately, little is known about the mechanisms of epithelial tolerance to bacteria. Our long-term goal is to understand the mechanisms of intestinal tolerance to commensal bacteria. We have found that bacterial lipopolysaccharide (LPS)-induced expression of the A20 deubiquitinase is necessary and sufficient for the development of tolerance to LPS, the TLR4 ligand, in enterocytes. A20 induction may be also responsible for enterocyte tolerance and cross-tolerance to the ligands of TLR3 and TLR9, but not TLR5 ligand flagellin (Fla). Because Fla induces the CYLD deubiquitinase, but not A20, it is possible that CYLD specifically inhibits TLR5 signaling. We hypothesize that A20 and CYLD promote tolerance to ligands of TLR3/TLR4/TLR9 and TLR5, respectively, which will be tested in 2 specific aims: 1. Assess role of A20 in tolerance to TLR ligands in intestinal epithelium by determining responses to different TLR ligands in enterocytes following forced expression or small interfering RNA (siRNA) silencing of A20. 2. Determine the role of CYLD in enterocyte tolerance to Fla. Induction of CYLD mRNA and protein by various TLR ligands will be measured using Northern and Western blots. Effects of CYLD ectopic expression and siRNA silencing on activation of inflammatory signaling by different TLR ligands will be used to elucidate the role and specificity of inhibitory effect of this deubiquitinase. CYLD expression in normal and inflamed intestine will be examined using immunofluorescence microscopy. This pilot study will define the key processes responsible for the development of tolerance to different TLR ligands in the intestine. Dissecting the mechanisms of intestinal tolerance will lead to better understanding of the pathogenesis of the intestinal inflammatory disorders such as necrotizing enterocolitis, and, ultimately, better therapies. Intestinal inflammatory disorders are caused by failure to establish and/or maintain tolerance to bacteria that populate the gut. We propose to elucidate the mechanisms of intestinal tolerance to bacterial components. Our findings will improve understanding of intestinal inflammatory diseases such as necrotizing enterocolitis, and suggest therapies aimed at augmenting tolerance to intestinal bacteria.
| AWARD OVERVIEW |
| Award Number |
5R21AI083612-02 REVISED |
Funding Agency |
Department of Health and Human Services |
| Total Award Amount |
$400,000 |
Project Location - City |
Los Angeles |
| Award Date |
08/13/2009 |
Project Location - State |
CA |
| Project Status |
Completed |
Project Location - Zip |
90027-6062
|
| Jobs Reported |
1.02 |
Congressional District |
33 |
| Project Location - Country |
US |
|
|
Recipient Information
(Grants)
| Recipient Information (Grants) |
|
Recipient Name
|
THE CHILDRENS HOSPITAL LOS ANGELES |
| Recipient DUNS Number |
052277936
|
| Recipient Address |
4650 W SUNSET BLVD |
| Recipient City |
LOS ANGELES |
| Recipient State |
California |
| Recipient Zip |
90027-6062 |
| Recipient Congressional District |
33 |
| Recipient Country |
USA |
Required to Report Top 5 Highly Compensated Officials |
No |
Projects and Jobs Information
| Projects and Jobs Information |
| Project Title |
TOLERANCE TO TLR LIGANDS IN THE INTESTINAL EPITHELIUM |
| Project Status |
Completed |
| Final Project Report Submitted |
Yes |
| Project Activities Description |
Medical Research, General/Other |
| Quarterly Activities/Project Description |
During the last quarter we accomplished tasks under Specific Aim 2 to establish effects of CYLD ectopic expression or silencing on responses and tolerance to Toll-like receptor ligands.
CYLD cDNA was amplified using RT-PCR with (poly-A)+ RNA from IEC-6 cells treated with flagellin for 1 h. The amplification product was cloned into the mammalian expression vector pcDNA3-V5. Expression of V5 epitope-tagged CYLD protein directed by the pcDNA3-CYLD-V5 plasmid in HEK293 cells was verified by Western blotting with V5 antibodies. To achieve ectopic expression of CYLD, IEC-6 cells were transiently transfected with pcDNA3-CYLD-V5 using the Nucleofector, and CYLD expression was confirmed by Western blotting. The resulting transfectants were treated for 10 min with Pam3CSK4 (TLR2 ligand), dsRNA (TLR3 ligand), LPS (TLR4 ligand), flagellin from S. typhimurium (TLR5 ligand), or CpG DNA (TLR9 ligand). Activating phosphorylation of p38 was examined by Western blotting with anti-phospho-p38 antibodies. Expression of CYLD did not appreciably alter phosphorylation of p38 by itself, and did not block phosphorylation induced by Pam3CSK4, dsRNA, LPS, or CpG DNA. However, there was significant attenuation of flagellin-induced phosphorylation.
CYLD siRNA was prepared by T7-directed transcription of CYLD template with subsequent cleavage of the resulting dsRNA with the ShortCut endonuclease. The mixture of 21 bp RNA duplexes complexed with Lipofectamine was used to transfect IEC-6 cells. 12 h post transfection, basal CYLD expression was reduced to about 20-30% of the original level. Transfection with CYLD siRNA, but not with control LEU2 siRNA, also significantly decreased flagellin-induced expression of CYLD, and largely prevented establishment of tolerance to flagellin. CYLD siRNA did not have appreciable effect on tolerance to LPS in IEC-6 cells.
These results support the role of the CYLD deubiquitinase in specific tolerance of enterocytes to the TLR5 ligand flagellin. |
| Jobs Created |
1.02 |
| Description of Jobs Created |
Recovery Act funds are supporting the employment of research personnel including research faculty and a research technician. |
Purchaser Information
(Grants)
| Purchaser Information |
| Contracting Office ID |
Not Reported |
| Contracting Office Name |
Not Available |
| Contracting Office Region |
Not Available |
| TAS Major Program |
75-0900 |
| Award Information |
| Award Date |
08/13/2009 |
| Award Number |
5R21AI083612-02 REVISED |
| Order Number |
|
| Award Type |
Grants |
| Funding Agency ID |
75 |
| Funding Agency Name |
Department of Health and Human Services |
| Funding Office Name |
Not Available |
| Awarding Agency ID |
75 |
| Awarding Agency Name |
Department of Health and Human Services |
| Amount of Award |
$400,000 |
| Funds Invoiced/Received |
$343,315 |
| Expenditure Amount |
$343,315 |
| Infrastructure Expenditure Amount |
$0 |
| Infrastructure Purpose and Rationale |
Not Reported |
| Infrastructure Point of Contact Name |
Not Reported |
| Infrastructure Point of Contact Email |
Not Reported |
| Infrastructure Point of Contact Phone |
Not Reported |
| Infrastructure Point of Contact Address |
Not Reported |
| Infrastructure Point of Contact City |
Not Reported |
| Infrastructure Point of Contact State |
Not Reported |
| Infrastructure Point of Contact Zip |
Not Reported |
Product or Service Information
(Grants)
| Product or Service Information |
| Primary Activity Code |
H01 |
| Activity Description |
Medical Research, General/Other |
| Sub-Awards Information |
| Sub-awards to Organizations |
0 |
| Sub-award Amounts to Organizations |
$0 |
| Sub-Awards to Individuals |
0 |
| Sub-Award Amounts to Individuals |
$0 |
| Number of Sub-awards less than $25,000/award |
0 |
| Amount of Sub-awards less than $25,000/award |
$0 |
| Number of payments to vendors greater than $25,000 |
0 |
| Total Amount of payments to vendors greater than $25,000/award |
$0 |
| Number of payments to vendors less than $25,000/award |
72 |
| Total Amount of payments to vendors less than $25,000/award |
$18,236 |
| Location Information |
| Latitude, Longitude |
34º 6' 25",
-118º 17' 23" |
| Congressional District |
33 |
| Address 1 |
4650 Sunset Blvd, M.S. #97 |
| Address 2 |
|
| City |
Los Angeles |
| County |
Los Angeles |
| State |
CA |
| Zip |
90027-6062 |
|
 |